New mimic of relapse or regional lymph node metastasis in a cancer survivor: a case of mRNA COVID-19 vaccine-induced lymphadenitis with high FDG uptake

Immunol Med. 2022 Mar;45(1):45-47. doi: 10.1080/25785826.2021.1999786. Epub 2021 Dec 16.

Abstract

Western countries that were first to administer the COVID-19 vaccination report cases of vaccine-induced axillary lymphadenitis with high FDG uptake. However, no such findings have been reported from any Asian countries. We report here a confusing case of a 31-year-old female cancer survivor with high FDG uptake in her axillary lymph nodes, suggesting recurrence, following mRNA COVID-19 vaccination. Although the value of SUVmax was elevated (12.7), additional imaging revealed that her lymphatic lesions were benign, and they resolved spontaneously. This case of a strong immune reaction to COVID-19 vaccination in regional lymph nodes is the first reported in a Japanese patient. We should be aware of this new mimic and optimize diagnostic imaging methods accordingly in the era of COVID-19.

Keywords: COVID-19 vaccination; FDG-PET; axillary lymphadenitis; metastasis; relapse.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • COVID-19 Vaccines
  • COVID-19*
  • Cancer Survivors*
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Lymphadenitis* / chemically induced
  • Lymphadenitis* / diagnosis
  • Lymphatic Metastasis
  • Neoplasm Recurrence, Local
  • RNA, Messenger
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines
  • RNA, Messenger
  • Fluorodeoxyglucose F18